Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Financial Results

Every financial results filing by a US-listed company that our alert engine sent, newest first.

4:16 PM ET 8-K
Financial Results Tenon Medical, Inc. TNON

Tenon Medical Financial Results

Tenon Medical reported third quarter 2026 revenue of $1.4 million, a 22% increase year-over-year, driven by the commercial launch of its 3D-printed lateral screw for the SImmetry+ system. The company strengthened its balance sheet by raising $15.6 million in gross proceeds, repaying $5.12 million in convertible notes, and ending the quarter with $8.3 million in cash.

4:16 PM ET 10-Q
Financial Results Vyome Holdings, Inc HIND

Vyome Holdings Q3 2026 Results: Net Loss of $885K, Loss Narrows

Vyome Holdings reported a net loss of $2.64 million for the nine months ended September 30, 2026, a significant improvement from the $9.20 million loss in the prior year period which was impacted by high transactional fees. The company strengthened its cash position to $6.96 million through ATM financing activities, while research and development expenses increased substantially to $1.58 million.

Key figure
Net loss $885K
4:16 PM ET 8-K
Financial Results GCT Semiconductor Holding, Inc. GCTS

GCT Semiconductor Holding Financial Results

GCT Semiconductor reported Q3 2026 financial results with revenue increasing 148.6% year-over-year to $1.1 million. The company highlighted that year-to-date 5G chipset shipments exceeded 11,300 units and expanded its addressable market into terrestrial-based location services.

Term
Q3 2026

“We continued to make progress across our 5G customer programs in the third quarter, advancing integration and certification work with existing customers while expanding the range of applications our 5G chipsets can serve.”

John Schlaefer, Chief Executive Officer of GCT
4:16 PM ET 10-Q
Financial Results Assembly Biosciences, Inc. ASMB

Assembly Biosciences Q3 2026 Results: Net Loss of $20.3M, Loss Widens

Assembly Biosciences, Inc. is a non-accelerated filer and smaller reporting company focused on therapeutic product candidates, primarily through a collaboration with Gilead Sciences. As of September 30, 2026, the company remains pre-revenue and unprofitable, relying on third-party CROs and collaborators for clinical development and manufacturing.

Key figure
Net loss $20.3M
4:16 PM ET 8-K
Financial Results Rocket Pharmaceuticals, Inc. RCKT

Rocket Pharmaceuticals Financial Results

Rocket Pharmaceuticals reported third quarter 2026 financial results, highlighting FDA alignment on the pivotal Phase 2 trial for RP-A501 in Danon disease with dosing completion expected by mid-2027. The company ended the quarter with $279.4 million in cash and investments, which is expected to fund operations into the third quarter of 2028.

Term
Q3 2026

“With FDA alignment on the pivotal RP-A501 trial in Danon disease, our priority is to complete dosing by mid-2027. We are also advancing our broader cardiovascular portfolio, with dosing initiated in the Phase 1 trial of RP-A701 for BAG3-DCM and continued FDA engagement on a potential pivotal study of RP-A601 in PKP2-ACM. Commercial readiness for KRESLADI and activation of our first Qualified Treatment Centers bring us closer to treating eligible children. Our financial resources and the additional flexibility provided by the Hercules facility support these priorities as we work toward our next clinical and commercial milestones.”

Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals
4:16 PM ET 8-K
Financial Results QXO, Inc. QXO

QXO Financial Results

QXO, Inc. reported third quarter 2026 financial results, including net sales of $4.9 billion and an adjusted EBITDA of $557 million. The results reflect the integration of legacy Beacon, Kodiak, and TopBuild businesses, with management targeting $50 billion in annual revenue within the decade. Additionally, the Board of Directors authorized a new $500 million common stock repurchase program.

“Our organic daily revenue trends improved for the second consecutive quarter despite a soft construction market. Companywide pricing increased 2.2% year over year. We’re prioritizing higher-margin products; in Roofing and Waterproofing, complementary product sales grew 4.2%, and TRI-BUILT reached a record 10.6% of sales. Mechanical insulation distribution revenue grew 16%, supported by strong data center demand.”

Brad Jacobs, chairman and chief executive officer of QXO

“We’re on track to reach $4 billion in adjusted EBITDA by 2030 from the businesses we already own and $50 billion in annual revenue within the decade through organic growth and disciplined acquisitions.”

Brad Jacobs, chairman and chief executive officer of QXO
4:16 PM ET 10-Q
Financial Results ARC Group Acquisition I Corp. ARCL

ARC Group Acquisition I Q3 2026 Results: Turns Profitable, Net Income $720K

ARC Group Acquisition I Corp. reported a net income of $1,318,548 for the nine months ended September 30, 2026, primarily driven by $1,822,314 in interest income from its trust account. The company completed its initial public offering in May 2026, resulting in $122,572,314 held in trust and 12,075,000 Class A ordinary shares subject to possible redemption.

Key figure
Net income $720K
4:16 PM ET 8-K
Financial Results NeoVolta Inc. NEOV

NeoVolta Financial Results

NeoVolta reported financial results for the quarter ended September 30, 2026, showing a sequential revenue rebound to $2.8 million driven by its residential third-party ownership (TPO) platform. The company also highlighted a $116 million Master Purchase Agreement for utility-scale products and a strategic 9 GWh battery cell supply collaboration with SK On.

Term
Q1 2027
4:16 PM ET 10-Q
Financial Results Equillium, Inc. EQ

Equillium Q3 2026 Results: Net Loss of $4.58M, Loss Widens

Equillium, Inc. reported a net loss of $4.6 million for the third quarter of 2026, with cash and cash equivalents increasing to $53.3 million as of September 30, 2026, following a private placement. Subsequent to the quarter-end, the company raised an additional $20.0 million in gross proceeds, which management believes will fund operations for at least the next 12 months.

Key figure
Net loss $4.58M
4:16 PM ET 10-Q
Financial Results XTI Aerospace, Inc. XTIA

XTI Aerospace Q3 2026 Results: Turns Profitable, Net Income $26M

XTI Aerospace reported total assets of $69.9 million as of September 30, 2026, a decrease from $81.2 million at year-end 2025, primarily driven by a reduction in cash and the disposal of its discontinued Inpixon Business. The company's balance sheet reflects significant liabilities including a $24.5 million warrant liability and the introduction of a $5.9 million asset-based revolving line of credit.

Key figure
Net income $26M
4:16 PM ET 8-K
Financial Results Flowers Foods Inc FLO

Flowers Foods Financial Results

Flowers Foods reported third quarter 2026 net sales of $1.169 billion, a 4.7% decrease year-over-year as favorable pricing was offset by lower volumes. Net income fell 63.6% to $14.4 million due to higher logistics costs and marketing investments, leading the company to lower its full-year 2026 financial guidance.

Term
12 weeks

“Our third-quarter results reflect a continued challenging operating environment, driven by pressure on household budgets, evolving consumer behavior and heightened promotional activity, as well as areas where we need to move faster with focused execution.”

Ryals McMullian, chairman and CEO of Flowers Foods

“While it will take time for our initiatives to translate more fully into results, we believe they are putting Flowers on a stronger path forward. We expect the environment to remain challenging in the near term, but we remain confident in the long-term potential of the business.”

Ryals McMullian, chairman and CEO of Flowers Foods
4:16 PM ET 8-K
Financial Results BlossomHill Therapeutics, Inc. BLSM

BlossomHill Therapeutics Financial Results

BlossomHill Therapeutics reported third quarter 2026 financial results, ending the period with $224.9 million in cash and cash equivalents. The company aligned with the FDA on a Phase 2 dose for BH-30643 and plans to initiate the pivotal SOLARA-2 trial in Q1 2027 for patients with EGFR C797S-positive NSCLC.

Term
Q3 2026

“We are pleased to have aligned with the FDA on a recommended Phase 2 dose of 50 mg BID based on favorable PK, safety and efficacy data in the Phase 1 portion of the SOLARA trial. We are now preparing to initiate SOLARA-2, a single arm, pivotal Phase 2 trial designed to evaluate BH-30643 in both chemotherapy-naive and chemotherapy-pretreated patients with C797S-positive NSCLC after progression on a third-generation EGFR TKI.”

J. Jean Cui, Ph.D., Founder, President and Chief Executive Officer
4:16 PM ET 8-K
Financial Results Azitra, Inc. AZTR

Azitra Financial Results

Azitra, Inc. reported Q3 2026 financial results and provided updates on its dermatology pipeline, including positive ex vivo results for its ATR-COSF cosmetic program and the advancement of ATR-04 into Cohort 2 of its Phase 1/2 trial. The company highlighted that upcoming clinical data readouts could trigger an additional $5.25 million to $10.5 million in investment from existing institutional investors.

Term
Q3 2026

“During the third quarter and recent weeks, we made substantial progress with our two priority programs, generating encouraging results for ATR-COSF and advancing ATR-04 forward in the clinic while broadening its potential to benefit more patients.”

Francisco Salva, Chief Executive Officer

“The remainder of 2026 has the potential to be a defining period for Azitra as we expect to report initial results from our first in-human cosmetic study of ATR-COSF and topline data from Cohort 1 of our ATR-04 Phase 1/2 trial.”

Francisco Salva, Chief Executive Officer
4:16 PM ET 8-K
Financial Results Crescent Biopharma, Inc. CBIO

Crescent Biopharma Financial Results

Crescent Biopharma reported Q3 2026 financial results and provided clinical updates on its lead programs, including the completion of dose escalation for CR-001 in the Phase 1/2 ASCEND trial. The company expects initial monotherapy data for CR-001 in Q1 2027 and highlighted that over 2,000 patients are expected to be dosed across its portfolio by mid-2027.

Counterparty
Kelun-Biotech

“This has been a defining year for Crescent. We advanced three programs into the clinic and established a leading position in developing next generation IO and ADC combinations which we believe have the potential to redefine cancer care. Together with our partner Kelun-Biotech, we have achieved a remarkable nine IND clearances, and anticipate that more than 2,000 patients will be dosed across our portfolio by mid-2027.”

Joshua Brumm, chief executive officer of Crescent

“The team’s strong execution has positioned us for several meaningful clinical data readouts in 2027, beginning in the first quarter with monotherapy results from our global ASCEND trial of CR-001, including first-line NSCLC patients, followed by initial standard of care chemotherapy combination data from multiple tumor types.”

Joshua Brumm, chief executive officer of Crescent
4:15 PM ET 8-K
Financial Results KinderCare Learning Companies, Inc. KLC

KinderCare Learning Companies Financial Results

KinderCare Learning Companies reported third quarter 2026 revenue of $665.3 million, a 1.7% decrease year-over-year, and a net loss of $85.0 million. The results were impacted by lower enrollment at early childhood education centers and $83.4 million in impairment losses related to market capitalization declines and center closures.

“While third-quarter enrollment at KinderCare Learning Centers fell short of our expectations, recent improvements reinforce our confidence in the operational changes we've made.”

Tom Wyatt, Chairman and Chief Executive Officer

“We know families face tough financial choices, and we’re focused on demonstrating the value of KinderCare’s high-quality education and care across all of our brands.”

Tom Wyatt, Chairman and Chief Executive Officer
4:15 PM ET 8-K
Financial Results Horizon Kinetics Holding Corp HKHC

Horizon Kinetics Holding Financial Results

Horizon Kinetics Holding Corp reported Q3 2026 financial results, including a net loss of $18.4 million primarily driven by unrealized declines in the fair value of key investment holdings. Despite the quarterly loss, year-to-date net income remains positive at $35.8 million, and the company's Board authorized a new $25 million share repurchase program and declared a $0.13 per share dividend.

Term
Q3 2026
4:15 PM ET 10-Q
Financial Results Rekor Systems, Inc. REKR ▶ Call

Rekor Systems Q3 2026 Results: Net Loss of $2.86M, Loss Narrows

Rekor Systems, Inc. reported a decrease in revenue to $10.9 million for the quarter ended September 30, 2026, compared to $14.2 million in the prior year. Despite the revenue decline, the company significantly reduced its net loss to $2.9 million for the quarter, aided by a $3.9 million gain on lease remeasurement and lower overall operating expenses.

Key figure
Net loss $2.86M
4:15 PM ET 10-Q
Financial Results Intellicheck, Inc. IDN ▶ Call

Intellicheck Q3 2026 Results: Net Income $471K, Up 62.4% YoY

Intellicheck, Inc. reported a net income of $1.77 million for the nine months ended September 30, 2026, a significant improvement from a net loss of $279,000 in the prior year period. Total revenues grew to $17.2 million for the nine-month period, and the company maintained a strong liquidity position with $13.17 million in cash and cash equivalents.

Key figure
Net income $471K · +62.4% YoY
4:15 PM ET 8-K
Financial Results Merlin, Inc. MRLN

Merlin Financial Results

Merlin, Inc. reported Q3 2026 revenue of $3.5 million and GAAP net income of $73.8 million, a significant shift from the prior quarter's loss. The company highlighted new contract wins with USSOCOM and USAFRICOM and stated its 2027 plan aims to reduce operating expenses to extend its cash runway into 2029.

Term
Q3 2026

“The new $8.9 million task order with USSOCOM moves our C-130J autonomy program into its integration phase, laying the groundwork for future flight demonstrations and production revenue with SOCOM and ultimately the global C-130J fleet including hundreds of aircraft.”

Matt George, CEO of Merlin

“the goal of our planning process is to ensure that we not only meet the opportunities presented by our current contracts, but also the broader market potential we detailed on last quarter’s call. We believe that it is imperative for Merlin to continue to advance the Merlin Pilot, but it is also imperative that we demonstrate discipline in the investments we make along the way.”

Matt George, CEO of Merlin
4:15 PM ET 10-Q
Financial Results Lgam Private Credit LLC

Lgam Private Credit Q3 2026 Results: Net Income $3.05M, Down 18.2% YoY

LGAM Private Credit LLC reported total investment income of $12.3 million for the quarter ended September 30, 2026, and net investment income of $5.4 million. The company's net asset value per unit decreased to $19.35 from $19.93 at the end of 2025, primarily driven by $6.5 million in net unrealized depreciation on investments during the first nine months of the year.

Key figure
Net income $3.05M · -18.2% YoY
4:15 PM ET 10-Q
Financial Results U S Global Investors Inc GROW

U S Global Investors Q1 2026 Results: Net Income $171K, Down 88.7% YoY

U.S. Global Investors reported net income of $171,000 for the quarter ended September 30, 2026, a significant decrease from $1.5 million in the prior year period, primarily due to lower net investment income. Operating revenues increased to $2.66 million from $2.25 million, while the company maintained a strong cash position of $25.3 million.

Key figure
Net income $171K · -88.7% YoY
4:14 PM ET 10-Q
Financial Results Azitra, Inc. AZTR

Azitra Q3 2026 Results: Net Loss of $2.95M, Loss Widens

Azitra, Inc. reported a net loss of $10.2 million for the nine months ended September 30, 2026, compared to $8.7 million in the prior year period. The company significantly strengthened its cash position to $3.8 million through a $10.4 million private placement and warrant exercises, while continuing to invest heavily in research and development for its synthetic biology dermatology platform.

Key figure
Net loss $2.95M
4:14 PM ET 10-Q
Financial Results Merlin, Inc. MRLN

Merlin Q3 2026 Results: Turns Profitable, Net Income $73.8M

Merlin, Inc. reported a significant increase in revenue to $3.46 million for the quarter ended September 30, 2026, and achieved a net income of $73.8 million, primarily driven by a $103.6 million gain from the change in fair value of warrant liabilities. Despite the quarterly profit, the company maintains an accumulated deficit of $626.1 million and recorded a net loss of $75.0 million for the nine-month period.

Key figure
Net income $73.8M
4:14 PM ET 10-Q
Financial Results Audax Credit BDC Inc.

Audax Credit BDC Q3 2026 Results: Net Income $6.75M, Up 13.5% YoY

Audax Credit BDC Inc. reported a net increase in net assets resulting from operations of $13.2 million for the nine months ended September 30, 2026, down from $19.7 million in the prior year period. The decrease was primarily driven by higher net realized and unrealized losses on investments totaling $9.7 million and a decline in total investment income to $27.1 million.

Key figure
Net income $6.75M · +13.5% YoY
4:14 PM ET 8-K
Financial Results Transact Technologies Inc TACT

Transact Technologies Financial Results

TransAct Technologies reported preliminary Q3 2026 financial results with net sales of $14.4 million, up 10% year-over-year, driven by a 33% increase in food service technology revenue. The company reported a net loss of $0.44 million and revised its full-year 2026 revenue guidance downward to $55-$56 million due to softening demand in the Casino and Gaming segment.

Term
Q3 2026

“Our food service technology business drove a strong third quarter, with FST revenue up 33% year-over-year with growth across hardware, software and labels. We sold 2,346 BOHA! units in the quarter, and software revenue grew approximately 61% as pricing actions, new account wins and bundled software packages take hold across our installed base.”

John Dillon, Chief Executive Officer of TransAct

“Casino and Gaming softened in the quarter, consistent with the cyclicality that we have seen in the past, and we expect the softer demand environment to continue into the fourth quarter. However, the fundamentals of this business are unchanged.”

John Dillon, Chief Executive Officer of TransAct
4:14 PM ET 10-Q
Financial Results Antares Strategic Credit Fund II LLC

Antares Strategic Credit Fund II Q3 2026 Results: Net Income $1.87M, Up 47.5% YoY

For the nine months ended September 30, 2026, Antares Strategic Credit Fund II LLC reported total investment income of $11.0 million and net investment income of $5.3 million. The fund's net asset value per share decreased to $24.76 from $25.28 at the end of 2025, primarily due to net unrealized depreciation on investments and distributions declared.

Key figure
Net income $1.87M · +47.5% YoY
4:14 PM ET 10-Q
Financial Results Arcadia Biosciences, Inc. RKDA

Arcadia Biosciences Q3 2026 Results: Net Income $1.75M, Up 105.0% YoY

Arcadia Biosciences reported a net loss of $8.9 million for the nine months ended September 30, 2026, compared to a $1.0 million loss in the prior year, primarily driven by valuation losses on financing activities. Total revenues increased to $4.16 million for the nine-month period, while the company strengthened its cash position to $2.84 million through various inducement offers and PIPE financing.

Key figure
Net income $1.75M · +105.0% YoY
4:14 PM ET 10-Q
Financial Results Obsidian Therapeutics, Inc. OBX

Obsidian Therapeutics Q3 2026 Results: Net Loss of $50.7M, Loss Widens

Obsidian Therapeutics is a clinical-stage biopharmaceutical company focused on developing amsoki-cel (formerly OBX-115). As of November 9, 2026, the company had 61,774,046 shares of common stock outstanding and continues to incur significant financial losses to fund its research and development programs.

Key figure
Net loss $50.7M
4:13 PM ET 8-K
Financial Results Serina Therapeutics, Inc. SER

Serina Therapeutics Financial Results

Serina Therapeutics reported third quarter 2026 financial results and provided a clinical update on its SER-252 program for Parkinson's disease. The company has advanced to Cohort 2 of its registrational study following a positive safety review, with topline single-ascending-dose data expected in the first half of 2027.

“We are excited about the achievement of important clinical milestones for SER-252 in Parkinson's disease, advancing from the initial evaluation of our lowest-dose cohort into the next stage of dose escalation. Importantly, the blinded pharmacokinetic observations from Cohort 1 showed the sustained drug exposure SER-252 was designed to achieve, and the independent Safety Monitoring Committee recommended proceeding with continued development.”

Steve Ledger, Chief Executive Officer
4:13 PM ET 8-K
Financial Results Soundthinking, Inc. SSTI

Soundthinking Financial Results

SoundThinking reported third quarter 2026 financial results with revenue of $25.0 million, which remained flat year-over-year. The company reported a GAAP net loss of $8.5 million, widened from a $2.0 million loss in the prior year, largely due to costs associated with its pending acquisition by Transom Capital Group. The company expects to close the Transom Transaction, which values the company at up to $159 million including contingent value rights, in the fourth quarter of 2026.

Term
Q3 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.